This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lounis, N.
Right arrow Articles by Grosset, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lounis, N.
Right arrow Articles by Grosset, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2001, p. 3482-3486, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3482-3486.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Effectiveness of Once-Weekly Rifapentine and Moxifloxacin Regimens against Mycobacterium tuberculosis in Mice

Nacer Lounis,1,* Abdelhalim Bentoucha,1 Chantal Truffot-Pernot,1 Baohong Ji,1 Richard J. O'Brien, Andrew Vernon, Giorgio Roscigno,3 and Jacques Grosset1

Laboratoire de Bactériologie, Faculté de Médecine Pitié-Salpêtrière, Paris 75634, France1; Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia 303332; and Global Alliance for TB Drug Development, New York, New York 100383

Received 16 July 2001/Returned for modification 20 August 2001/Accepted 20 September 2001

Mice infected with 1.6 × 107 CFU of Mycobacterium tuberculosis were treated 14 days later for 6 months with a regimen of once-weekly 10 mg of rifapentine and 75 mg of isoniazid per kg of body weight supplemented with either 150 mg of streptomycin per kg or 100 mg of moxifloxacin per kg during either both the 2-week daily initial and once-weekly continuation phases or only in the daily 2-week initial phase. On completion of treatment, all lung cultures were negative, except for three mice, each with a single colony: two whose rifapentine-isoniazid regimen was supplemented with streptomycin during the whole course of therapy and one whose rifapentine-isoniazid regimen had no initial daily phase, but was supplemented with streptomycin and moxifloxacin during the whole course of therapy. After 3 months of follow-up, positive lung cultures were obtained from 61 and 56% of mice supplemented with streptomycin during either the full course of therapy or only the daily 2-week initial phase, respectively, and 15 and 50% of mice supplemented with moxifloxacin during either the full course of therapy or only the daily 2-week initial phase, respectively. These results suggest that moxifloxacin has sterilizing activity against M. tuberculosis.

* Corresponding author. Mailing address: Laboratoire de Bactériologie-Hygiène, Faculté de Médecine Pitié-Salpêtrière, 91 Boulevard de l'Hôpital, 75634 Paris, Cedex 13, France. Phone: (33) 1 40 77 97 46. Fax: (33) 1 45 82 75 77. E-mail: lounis{at}chups.jussieu.fr.

Antimicrobial Agents and Chemotherapy, December 2001, p. 3482-3486, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3482-3486.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • van den Boogaard, J., Kibiki, G. S., Kisanga, E. R., Boeree, M. J., Aarnoutse, R. E. (2009). New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development. Antimicrob. Agents Chemother. 53: 849-862 [Full Text]  
  • Veziris, N., Ibrahim, M., Lounis, N., Chauffour, A., Truffot-Pernot, C., Andries, K., Jarlier, V. (2009). A Once-Weekly R207910-containing Regimen Exceeds Activity of the Standard Daily Regimen in Murine Tuberculosis. Am. J. Respir. Crit. Care Med. 179: 75-79 [Abstract] [Full Text]  
  • Lounis, N., Gevers, T., Van Den Berg, J., Andries, K. (2008). Impact of the Interaction of R207910 with Rifampin on the Treatment of Tuberculosis Studied in the Mouse Model. Antimicrob. Agents Chemother. 52: 3568-3572 [Abstract] [Full Text]  
  • Ji, B., Chauffour, A., Robert, J., Jarlier, V. (2008). Bactericidal and Sterilizing Activities of Several Orally Administered Combined Regimens against Mycobacterium ulcerans in Mice. Antimicrob. Agents Chemother. 52: 1912-1916 [Abstract] [Full Text]  
  • Lounis, N., Veziris, N., Chauffour, A., Truffot-Pernot, C., Andries, K., Jarlier, V. (2006). Combinations of R207910 with Drugs Used To Treat Multidrug-Resistant Tuberculosis Have the Potential To Shorten Treatment Duration. Antimicrob. Agents Chemother. 50: 3543-3547 [Abstract] [Full Text]  
  • Burman, W. J., Goldberg, S., Johnson, J. L., Muzanye, G., Engle, M., Mosher, A. W., Choudhri, S., Daley, C. L., Munsiff, S. S., Zhao, Z., Vernon, A., Chaisson, R. E., and the Tuberculosis Trials Consortium, (2006). Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis. Am. J. Respir. Crit. Care Med. 174: 331-338 [Abstract] [Full Text]  
  • Nardell, E. A., Rubin, E. J. (2005). Once upon a Time...: Improved Intermittent Therapy for Tuberculosis--Fact or Fable?. Am. J. Respir. Crit. Care Med. 172: 1361-1362 [Full Text]  
  • Rosenthal, I. M., Williams, K., Tyagi, S., Vernon, A. A., Peloquin, C. A., Bishai, W. R., Grosset, J. H., Nuermberger, E. L. (2005). Weekly Moxifloxacin and Rifapentine Is More Active Than the Denver Regimen in Murine Tuberculosis. Am. J. Respir. Crit. Care Med. 172: 1457-1462 [Abstract] [Full Text]  
  • Nuermberger, E., Tyagi, S., Williams, K. N., Rosenthal, I., Bishai, W. R., Grosset, J. H. (2005). Rifapentine, Moxifloxacin, or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model. Am. J. Respir. Crit. Care Med. 172: 1452-1456 [Abstract] [Full Text]  
  • Veziris, N., Lounis, N., Chauffour, A., Truffot-Pernot, C., Jarlier, V. (2005). Efficient Intermittent Rifapentine-Moxifloxacin-Containing Short-Course Regimen for Treatment of Tuberculosis in Mice. Antimicrob. Agents Chemother. 49: 4015-4019 [Abstract] [Full Text]  
  • Gordin, F. M. (2004). Rifapentine for the Treatment of Tuberculosis: Is It All It Can Be?. Am. J. Respir. Crit. Care Med. 169: 1176-1177 [Full Text]  
  • Nuermberger, E. L., Yoshimatsu, T., Tyagi, S., O'Brien, R. J., Vernon, A. N., Chaisson, R. E., Bishai, W. R., Grosset, J. H. (2004). Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis. Am. J. Respir. Crit. Care Med. 169: 421-426 [Abstract] [Full Text]  
  • Chan, C.-Y., Au-Yeang, C., Yew, W.-W., Leung, C.-C., Cheng, A. F. B. (2004). In Vitro Postantibiotic Effects of Rifapentine, Isoniazid, and Moxifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48: 340-343 [Abstract] [Full Text]  
  • Lu, T., Drlica, K. (2003). In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents. J Antimicrob Chemother 52: 1025-1028 [Abstract] [Full Text]  
  • O'Brien, R. J. (2003). Development of Fluoroquinolones as First-line Drugs for Tuberculosis--at Long Last!. Am. J. Respir. Crit. Care Med. 168: 1266-1268 [Full Text]  
  • Veziris, N., Truffot-Pernot, C., Aubry, A., Jarlier, V., Lounis, N. (2003). Fluoroquinolone-Containing Third-Line Regimen against Mycobacterium tuberculosis In Vivo. Antimicrob. Agents Chemother. 47: 3117-3122 [Abstract] [Full Text]  
  • Mitchison, D. A. (2003). Role of Isoniazid in Once-Weekly Rifapentine Treatment of Pulmonary Tuberculosis. Am. J. Respir. Crit. Care Med. 167: 1298-1299 [Full Text]  
  • Weiner, M., Burman, W., Vernon, A., Benator, D., Peloquin, C. A., Khan, A., Weis, S., King, B., Shah, N., Hodge, T., the Tuberculosis Trials Consortium, (2003). Low Isoniazid Concentrations and Outcome of Tuberculosis Treatment with Once-Weekly Isoniazid and Rifapentine. Am. J. Respir. Crit. Care Med. 167: 1341-1347 [Abstract] [Full Text]  
  • (2003). American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis. Am. J. Respir. Crit. Care Med. 167: 603-662 [Full Text]  
  • Hu, Y., Coates, A. R. M., Mitchison, D. A. (2003). Sterilizing Activities of Fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47: 653-657 [Abstract] [Full Text]  
  • Fattorini, L., Tan, D., Iona, E., Mattei, M., Giannoni, F., Brunori, L., Recchia, S., Orefici, G. (2003). Activities of Moxifloxacin Alone and in Combination with Other Antimicrobial Agents against Multidrug-Resistant Mycobacterium tuberculosis Infection in BALB/c Mice. Antimicrob. Agents Chemother. 47: 360-362 [Abstract] [Full Text]  
  • Yoshimatsu, T., Nuermberger, E., Tyagi, S., Chaisson, R., Bishai, W., Grosset, J. (2002). Bactericidal Activity of Increasing Daily and Weekly Doses of Moxifloxacin in Murine Tuberculosis. Antimicrob. Agents Chemother. 46: 1875-1879 [Abstract] [Full Text]  
  • Bock, N. N., Sterling, T. R., Hamilton, C. D., Pachucki, C., Wang, Y.-C., Conwell, D. S., Mosher, A., Samuels, M., Vernon, A. (2002). A Prospective, Randomized, Double-Blind Study of the Tolerability of Rifapentine 600, 900, and 1,200 mg Plus Isoniazid in the Continuation Phase of Tuberculosis Treatment. Am. J. Respir. Crit. Care Med. 165: 1526-1530 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»